|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 3. Expression of candidate targets for human SPRY2-mediated
antagonism of Fgf genes and Fgfr genes in the embryonic kidney. Fgf2
is expressed in the ureteric bud, mesenchymal cells and assembling nephrons,
and human SPRY2 expression leads to reduced Fgf2 gene
expression in the ureteric bud (compare A with A',A''). Expression
of Fgf7, a stromal marker (Finch
et al., 1995), is also reduced because of human SPRY2
expression when compared with the normal kidney (compare B with
B',B''), while Fgf8 remains unchanged
(C,C',C''). Fgf9 is again reduced, especially when the
transgene is inherited from both the female and male (compare D,D' with
D''). Fgfr1, which is expressed in mesenchymal cells and in
developing nephrons (E arrows), is not detected in more mature nephrons, owing
to human SPRY2 expression (compare E,E' with E'').
Expression of Fgfr2, Fgfr3 and Fgfr4 appeared to be
unchanged in the presence of human SPRY2 gene expression
(F-H''). (A-H'') E15.5. Scale bars: 100 µm. Fgfr, Fgf receptor;
WT, wild type; TG, explants containing human SPRY2.
|
